[go: up one dir, main page]

NO20064499L - Crystalline composition containing escitalopram oxalate - Google Patents

Crystalline composition containing escitalopram oxalate

Info

Publication number
NO20064499L
NO20064499L NO20064499A NO20064499A NO20064499L NO 20064499 L NO20064499 L NO 20064499L NO 20064499 A NO20064499 A NO 20064499A NO 20064499 A NO20064499 A NO 20064499A NO 20064499 L NO20064499 L NO 20064499L
Authority
NO
Norway
Prior art keywords
escitalopram oxalate
particles
composition containing
crystalline
crystalline composition
Prior art date
Application number
NO20064499A
Other languages
Norwegian (no)
Inventor
Ken Liljegren
Rikke Eva Humble
Kim Bojstrup Jensen
Troels Volsgaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34921251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064499(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20064499L publication Critical patent/NO20064499L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelse bringer for dagen krystallinske partikler av escitalopram-oksalat som enten har en bred partikkelstørrelsesfordeling eller omfatter minst 0,01 % (vekt/vekt) Z-4-(4-dimetylamino-1-(4-fluorfenyl)-but-1-enyl)-3-hydroksymetyl-benzonitril, partiklene er passende for anvendelse i direkte sammentrykking. Videre bringer oppfinnelsen for dagen en ny farmasøytisk enhetsdoseringsform inneholdende slike krystallinske partikler av escitalopram-oksalat samt fremgangsmåter for fremstilling av slike krystallinske partikler av escitalopram-oksalat Til sist tilveiebringer oppfinnelsen en fremgangsmåte for reduksjon av mengden av hydroksylinneholdende forurensninger i en løsning av citalopram eller escitalopram.The present invention brings about crystalline escitalopram oxalate particles which either have a wide particle size distribution or comprise at least 0.01% (w / w) Z-4- (4-dimethylamino-1- (4-fluorophenyl) but-1 -enyl) -3-hydroxymethyl-benzonitrile, the particles are suitable for use in direct compression. Furthermore, the present invention provides a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as processes for preparing such crystalline particles of escitalopram oxalate.

NO20064499A 2004-03-05 2006-10-04 Crystalline composition containing escitalopram oxalate NO20064499L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55090904P 2004-03-05 2004-03-05
DKPA200400382 2004-03-05
PCT/DK2005/000115 WO2005084643A1 (en) 2004-03-05 2005-02-21 Crystalline composition containing escitalopram oxalate

Publications (1)

Publication Number Publication Date
NO20064499L true NO20064499L (en) 2006-12-04

Family

ID=34921251

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064499A NO20064499L (en) 2004-03-05 2006-10-04 Crystalline composition containing escitalopram oxalate

Country Status (9)

Country Link
EP (1) EP1732514A1 (en)
JP (1) JP2007526262A (en)
AU (1) AU2005218713B2 (en)
BR (1) BRPI0508266A (en)
CA (1) CA2558198A1 (en)
EA (1) EA200601641A1 (en)
NO (1) NO20064499L (en)
NZ (1) NZ549100A (en)
WO (1) WO2005084643A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US8252336B2 (en) 2006-10-20 2012-08-28 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
EP2116231A1 (en) * 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
JP2018016569A (en) * 2016-07-26 2018-02-01 株式会社トクヤマ (1S) -1- [3- (Dimethylamino) propyl] -1- (4-fluorophenyl) -1,3-dihydroisobenzofuran-5-carbonitrile oxalate production method
JP6554245B1 (en) * 2019-01-31 2019-07-31 第一工業製薬株式会社 2,2'-bis (2-hydroxyethoxy) -1,1'-binaphthalene powder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
HRP20030744A2 (en) * 2001-05-01 2005-06-30 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (en) * 2001-06-25 2004-03-03 Lundbeck & Co As H PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND / OR OF THE S- OR R-CITALOPRAM THROUGH THE SEPARATION OF A MIXING OF R- AND S-CITALOPRAM
EA006213B1 (en) * 2001-07-31 2005-10-27 Х. Лундбекк А/С Crystalline composition containing escitalopram
AR040970A1 (en) * 2002-08-12 2005-04-27 Lundbeck & Co As H METHOD FOR THE SEPARATION OF INTERMEDIARIES THAT CAN BE USED FOR THE PREPARATION OF SCITALOPRAM
CA2511142A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
WO2004085416A1 (en) * 2003-03-24 2004-10-07 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate

Also Published As

Publication number Publication date
EP1732514A1 (en) 2006-12-20
AU2005218713B2 (en) 2009-11-19
NZ549100A (en) 2010-02-26
CA2558198A1 (en) 2005-09-15
EA200601641A1 (en) 2006-12-29
WO2005084643A1 (en) 2005-09-15
JP2007526262A (en) 2007-09-13
AU2005218713A1 (en) 2005-09-15
BRPI0508266A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
MXPA05010682A (en) Novel compounds.
TW200519075A (en) Novel compounds
WO2019191092A8 (en) Compounds for treating huntington's disease
TW200612892A (en) Novel compounds
MY145074A (en) Thiazolidin-4-one derivatives
TW200407305A (en) Novel compounds
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
EA200900828A1 (en) COMPOUNDS AND COMPOSITIONS AS AN INHIBITOR ACTIVITY OF THE CANANABINOID RECEPTOR 1
WO2009102893A3 (en) Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors
NO20082746L (en) Kinazolines useful as modulators for voltage controlled ion channels
AR111570A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY SELEXIPAG
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
PH12020550683A1 (en) Novel bradykinin b2 receptor antagonists
EA201000752A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING EZETIMIB
EP4501404A3 (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
JO2769B1 (en) Fast Dissociting Dopamine 2 Receptor Antagonists
GB0510143D0 (en) Novel compounds A1
EA200601194A1 (en) NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR
NZ786543A (en) Compounds active towards nuclear receptors
UA97826C2 (en) Fast dissociating dopamine 2 receptor antagonists

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application